Education
About Us
Working with TipRanks
Follow Us
Beyondspring Inc (BYSI)
NASDAQ:BYSI
BYSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.98 - $3.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)23.89K
Market Cap
$81.07M
Enterprise Value$98.35M
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$477.00K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding40,332,320
10 Day Avg. Volume22,743
30 Day Avg. Volume23,890
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue-68.39
Enterprise Value/Gross Profit-64.79
Enterprise Value/Ebitda-51.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.98 and its highest was $3.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $81.07M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is May 06, 2026 which is in 263 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on Aug 13, 2025. The company reported -$0.045 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.045.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 40,332,320 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.045 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.498%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
Beyondspring Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.43%
12-Months-Change
Fundamentals
Return on Equity
78.44%
Trailing 12-Months
Asset Growth
-36.44%
Trailing 12-Months
Company Description
Beyondspring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Technical Analysis
Adicet Bio
―
Precision BioSciences
―
ImageneBio
―
MAIA Biotechnology, Inc.
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
12.30%
Insiders
0.07% Mutual Funds
12.27% Other Institutional Investors
73.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---